|
| | Doxazosin Basic information |
| Product Name: | Doxazosin | | Synonyms: | [4-(4-amino-6,7-dimethoxy-quinazolin-2- yl)piperazin-1-yl]-(2,5-dioxabi cyclo[4.4.0]deca-6,8,10-trien-4-yl)methanone;DOXAZOSIN;DoxazosinMesylate77883-43-3/Base;DOXAZOSIN(SUBJECTTOPATENTFREE);[4-(4-amino-6,7-dimethoxy-2-quinazolinyl)-1-piperazinyl]-[(3S)-2,3-dihydro-1,4-benzodioxin-3-yl]methanone;Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl]-;UK 33,274;UK 33274 | | CAS: | 74191-85-8 | | MF: | C23H25N5O5 | | MW: | 451.48 | | EINECS: | 616-059-6 | | Product Categories: | API;API, Trade Name: Cardura & Carduran;Pharmaceutical;Doxazosin | | Mol File: | 74191-85-8.mol |  |
| | Doxazosin Chemical Properties |
| Melting point | 289-290°C | | Boiling point | 718.0±70.0 °C(Predicted) | | density | 1.371±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | Soluble in DMSO | | pka | 6.52±0.50(Predicted) | | form | Powder | | CAS DataBase Reference | 74191-85-8(CAS DataBase Reference) |
| | Doxazosin Usage And Synthesis |
| Description | Doxazosin mesylate is a selective alpha, blocker indicated for the treatment of
hypertension, reportedly of special benefit as a first-line agent in the most hypertonic
patient population. Another advantage of doxazosin is its favorable effect on blood lipids;
it significantly increases the HDL/total cholesterol ratio and decreases the total cholesterol
as well as triglycerides levels. | | Originator | Pfizer (United Kingdom) | | Uses | ACIPHEX therapeutic Erosive or Ulcerative Gastroesophageal Reflux Disease | | Definition | ChEBI: A member of the class of quinazolines that is quinazoline substituted by an amino group at position 4, methoxy groups at positions 6 and 7 and a piperazin-1-yl group at position 2 which in turn is substituted by a 2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl
roup at position 4. An antihypertensive agent, it is used in the treatment of high blood pressure. | | Brand name | Cardura (Pfizer);Carduran. | | General Description | Doxazosin, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(1,4-benzodioxan-2-ylcarbonyl)piperazine(Cardura), is a quinazoline compound that selectively inhibitsthe α1-subtype of α-adrenergic receptors. This agentis very useful in the management of hypertension associatedwith pheochromocytoma. | | Clinical Use | Alpha-adrenoceptor blocker:
Hypertension
Benign prostatic hyperplasia (BPH) | | Drug interactions | Potentially hazardous interactions with other drugs
Antidepressants: enhanced hypotensive effect with
MAOIs.
Avanafil, vardenafil, sildenafil and tadalafil: enhanced
hypotensive effect, avoid with tadalafil, start the
others at the lowest possible dose.
Beta-blockers: enhanced hypotensive effect;
increased risk of first dose hypotensive effect.
Calcium-channel blockers: enhanced hypotensive
effect, increased risk of first dose hypotensive effect.
Diuretics: enhanced hypotensive effect, increased risk
of first dose hypotensive effect.
Moxisylyte: possibly severe postural hypotension
when used in combination. | | Metabolism | Doxazosin is extensively metabolised in the liver,
and excreted in faeces as inactive metabolites
(6-hydroxydoxazosin) and a small amount of unchanged
drug |
| | Doxazosin Preparation Products And Raw materials |
|
